Patient-reported outcomes and diabetes technology: a systematic review of the literature.
BACKGROUND
Advanced diabetes technology should have benefits not only in terms of clinical outcomes, but also in terms of patient-reported outcomes.


OBJECTIVE
The objective of this paper is to review the methodology and findings of studies that assessed the effects of diabetes technologies such as continuous subcutaneous insulin infusion (CSII), continuous glucose monitoring (CGM), and integrated CSII/CGM on patientreported outcomes.


METHODS
The existing literature in pediatric and adult patients is limited, so there is no conclusive evidence that use of CSII, CGM, or integrated CSII/CGM systems produce improved patient-reported outcomes, but most studies provide evidence that these technologies yield some patient-reported outcomes advantages, and few indicate any disadvantages.


CONCLUSIONS
We expect that more robust studies in the future will provide further evidence regarding the impact of these technologies for patient-reported outcomes, including general health-related quality-of-life, diabetesspecific quality-of-life, treatment satisfaction, and treatment preference.
Rubin
Richard R
RR
Department of Medicine, Johns Hopkins University School of Medicine; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. rrubin4@jhmi.edu
Peyrot
Mark
M
D001786:Blood Glucose / Q000032:analysis*; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems / Q000592:standards*; D018670:Monitoring, Ambulatory / Q000379:methods*; D017060:Patient Satisfaction
D001786:Blood Glucose; D007328:Insulin